4/17
11:04 pm
cslly
Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build "Australia's next CSL" [Yahoo! Finance]
Low
Report
Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build "Australia's next CSL" [Yahoo! Finance]
4/17
11:00 pm
cslly
Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build "Australia's next CSL"
Low
Report
Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build "Australia's next CSL"
4/17
11:00 pm
cslly
Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build "Australia's next CSL"
Low
Report
Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build "Australia's next CSL"
4/2
01:00 pm
cslly
At-risk Australians now have access to a cell-based flu vaccine on the National Immunisation Program
Low
Report
At-risk Australians now have access to a cell-based flu vaccine on the National Immunisation Program
3/28
03:00 am
cslly
Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients
Low
Report
Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients
3/28
03:00 am
cslly
Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients
Low
Report
Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients
3/27
01:12 pm
cslly
Hemophilia B Drug Market Size and Share to Grow by 2032, Assesses DelveInsight | Key Emerging Therapies - CSL222, SerpinPC, AskBio009, PF-06838435/fida, Marstacimab, FLT180a, Concizumab, Fitusiran [Yahoo! Finance]
Low
Report
Hemophilia B Drug Market Size and Share to Grow by 2032, Assesses DelveInsight | Key Emerging Therapies - CSL222, SerpinPC, AskBio009, PF-06838435/fida, Marstacimab, FLT180a, Concizumab, Fitusiran [Yahoo! Finance]
3/26
04:57 pm
cslly
Global Antithrombin Market Set for Robust Growth, Expected to Reach $809.2 Million by 2030 [Yahoo! Finance]
Low
Report
Global Antithrombin Market Set for Robust Growth, Expected to Reach $809.2 Million by 2030 [Yahoo! Finance]
3/19
07:09 am
cslly
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
Low
Report
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
3/19
07:00 am
cslly
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
Low
Report
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
3/12
12:11 pm
cslly
Solar Negotiators Becomes a Licensed Roofing Contractor [Yahoo! Finance]
Low
Report
Solar Negotiators Becomes a Licensed Roofing Contractor [Yahoo! Finance]
3/6
09:20 am
cslly
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season [Yahoo! Finance]
Low
Report
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season [Yahoo! Finance]
3/6
09:00 am
cslly
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
Low
Report
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
2/28
07:22 am
cslly
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress [Yahoo! Finance]
Neutral
Report
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress [Yahoo! Finance]
2/24
07:17 pm
cslly
An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 21% Undervalued [Yahoo! Finance]
Low
Report
An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 21% Undervalued [Yahoo! Finance]
2/23
07:12 am
cslly
Travere Therapeutics gains as EU backs kidney disease therapy [Seeking Alpha]
Low
Report
Travere Therapeutics gains as EU backs kidney disease therapy [Seeking Alpha]
2/15
12:14 pm
cslly
ABIONYX Pharma Acknowledges the Clinical Results of the Phase 3 AEGIS-II Study Evaluating the Efficacy and Safety of CSL Behring's Human-plasma-derived apoA-I, CSL112 [Yahoo! Finance]
Low
Report
ABIONYX Pharma Acknowledges the Clinical Results of the Phase 3 AEGIS-II Study Evaluating the Efficacy and Safety of CSL Behring's Human-plasma-derived apoA-I, CSL112 [Yahoo! Finance]
2/12
11:31 pm
cslly
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
Medium
Report
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
2/12
10:58 pm
cslly
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³ [Yahoo! Finance]
Medium
Report
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³ [Yahoo! Finance]
2/12
10:54 pm
cslly
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
Medium
Report
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
2/12
05:03 pm
cslly
CSL Says 1H Profit Rises, Boosts Dividend -- Update [MarketWatch]
Medium
Report
CSL Says 1H Profit Rises, Boosts Dividend -- Update [MarketWatch]
2/12
01:58 pm
cslly
CSL Limited falls after Phase 3 setback for key trial [Seeking Alpha]
Low
Report
CSL Limited falls after Phase 3 setback for key trial [Seeking Alpha]
2/11
05:54 pm
cslly
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human]) [Yahoo! Finance]
Medium
Report
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human]) [Yahoo! Finance]
2/11
05:47 pm
cslly
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
Medium
Report
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])